PP051. Budget impact analysis of maternal plasma PIGF concentrations in women with suspected pre-eclampsia: The potential for improved health service usage

Hunter, Rachael; Duckworth, Suzy; Seed, Paul; Shennan, Andrew; Chappell, Lucy C

doi:10.1016/j.preghy.2013.04.078

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 1972 potentially relevant references originally identified in the searches of test accuracy studies (see Chapter 4, Quantity and quality of research available), six 33,39,[93][94][95][96] appeared to provide information about economic studies and were retrieved for further scrutiny ( Figure 6). Three further documents reporting economic analyses were provided by companies in confidence, as part of the NICE Diagnostics Full-text articles retrieved (n = 9)…”

Section: Results Of the Review Of Economic Studiesmentioning

confidence: 99%

“…After scrutiny, two references were excluded because they were meeting abstracts 93,94 that duplicated existing full-text references, and one was excluded because it was a systematic review that did not include any relevant index tests. 95 This systematic review, by Meads et al, 95 reviewed diagnostic methods for PE, but did not include any of this assessment's index tests.…”

Section: Results Of the Review Of Economic Studiesmentioning

confidence: 99%

“…94 See Table 34 Cost of pregnancy surveillance and management of gestational hypertension in suspected PE presenting between 35 and 37 weeks of gestation -applies to all women testing negative/rule-out for PE Median time to delivery (days) PE 9 4-16 PELICAN study 5 No PE 16 6-23…”

mentioning

confidence: 99%

See 2 more Smart Citations

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Frampton

Jones

Rose

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. Health Technol Assess 2016;20(87).Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch ® ) and Current Contents ® / Clinical Medicine. This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/). Health Technology Assessment NICE TAR and DAREditorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 14/69/05. The protocol was agreed in March 2015. The assessment report began editorial review in September 2015 and was accepted for publication in June 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The ...

show abstract

Section: Results Of the Review Of Economic Studiesmentioning

confidence: 99%

Section: Results Of the Review Of Economic Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Frampton

Jones

Rose

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Hunter et al (10) only examined serum PGF level in pregnant women at risk for preeclampsia and found a negative predictive value of 98% in pregnancies less than 34 weeks and 69% in pregnancies more than 34 weeks for predicting preeclampsia in two weeks. They suggested that control of PGF levels below 34 weeks might be useful in predicting the development of preeclampsia.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Maternal Serum Soluble Fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio in Preeclamptic and Normotensive Pregnant Women

Kılık¹,

Mihmanlı²,

Cetin³

et al. 2019

eamr

View full text Add to dashboard Cite

It has been suggested that the underlying pathology in preeclampsia is inadequate trophoblastic invasion, abnormal placentation and extensive endothelial damage. The aim of this study was to compare soluble Fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PGF) levels and sFlt-1/PGF ratio between preeclamptic and normotensive pregnant women, and to determine the increase in sFlt-1, which is an important antiangiogenic factor in the development of preeclampsia. Methods: Following local ethics committee approval, this prospective study was carried out with 43 pregnant women, including 20 preeclamptic and 23 normotensive pregnancies, who were admitted to our clinic. The two groups were compared in terms of gestational characteristics, sFlt-1 levels, PGF levels and sFlt-1/PGF ratio. Results: Serum sFlt-1 levels and sFlt-1/PGF ratio were higher and serum PGF levels were lower in preeclamptic women compared to the control group. Conclusion: The sFlt-1/PGF ratio was significantly higher in preeclamptic pregnant women than in normotensive pregnant women. This higher ratio suggests that sFlt-1 has a role in the development of hypoxia and inadequate angiogenesis in preeclamptic pregnancies.

show abstract

Prediction and prevention of hypertensive disorders of pregnancy

et al. 2016

View full text Add to dashboard Cite

The most common classifications of hypertensive disorders of pregnancy consist of chronic hypertension, gestational hypertension, preeclampsia (PE) and superimposed PE. A common final pathophysiology of PE is endothelial dysfunction. The most successful translational research model for explaining the cause-effect relationship in the genesis of PE is the angiogenic/angiostatic balance theory, involving soluble fms-like tyrosine kinase 1 (sFlt-1), placental growth factor (PlGF) and soluble endoglin (sEng). In a systematic review of articles on the prediction of early-onset PE using angiogenesis-related factors, we revealed that the prediction of early-onset PE in the first trimester is clinically possible, but the prediction of early-onset PE in the early third trimester might be ideal. In addition, an onset threshold or a serial approach appeared to be clinically useful for predicting the imminent onset of PE, with onset at <4 weeks after blood sampling in the second and early third trimesters, because the positive likelihood ratio was >10 and the positive predictive value was >20%. The National Institute for Health and Care Excellence guidelines state that the Triage PlGF testing and Elecsys immunoassay for the sFlt-1/PlGF ratio could help to exclude PE in women with suspected PE at 20-34 weeks of gestation. Until now, we have not found any effective therapies to prevent PE. However, low-dose aspirin treatment starting at ⩽16 weeks of gestation might be associated with a marked reduction in PE. In addition, early statin treatment might prevent the occurrence of PE. Currently, a clinical trial using pravastatin for the prevention of PE is ongoing.

show abstract

PP051. Budget impact analysis of maternal plasma PIGF concentrations in women with suspected pre-eclampsia: The potential for improved health service usage

Cited by 3 publications

References 0 publications

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Comparison of Maternal Serum Soluble Fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio in Preeclamptic and Normotensive Pregnant Women

Prediction and prevention of hypertensive disorders of pregnancy

Contact Info

Product

Resources

About